No Data
Zynex CEO Reflects on 28 Years of Medical Device Innovation - ICYMI | NASDAQ:ZYXI
In Spite of Recent Selling, Insiders Still Have the Largest Holding in Zynex, Inc. (NASDAQ:ZYXI) With a 51% Ownership
HC Wainwright & Co. Reiterates Buy on Zynex, Maintains $16 Price Target
Zynex Analyst Ratings
H.C. Wainwright Maintains Zynex(ZYXI.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright analyst Yi Chen maintains $Zynex(ZYXI.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 27.9% and a total
Buy Rating Affirmed for Zynex on FDA Clearance and Solid Growth Prospects